Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Richland, WA, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Vivos Inc. (OTC: RDGL), a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in...
-
Richland WA , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTC PINK: RDGL) Vivos Inc is pleased to announce that all the debtholders of Vivos’ secured convertible debt have agreed to a ten...
-
Richland WA, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTC PINK: RDGL) Vivos Inc is pleased to announce that all the debtholders of Vivos convertible debt have agreed to a 10 day standstill,...
-
Richland, WA, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) finalizes its plan to introduce IsoPet® to the veterinarian community. IsoPet® was designated as a device by the FDA and the...
-
Richland, WA, July 30, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) obtains IsoPet trademark protection. The U.S. Patent and Trademark Office (“USPTO”) issued the Certificate of Registration...
-
Richland, WA, May 31, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) successfully treated canine soft tissue sarcoma with its proprietary IsoPet™ (RadioGel™), a hydrogel liquid containing tiny...
-
Richland, WA, May 01, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) announced today the results from the therapy for feline sarcoma. Five cats were treated at Washington...
-
Richland, WA, March 20, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) announced today that it added a new member on the Veterinary Medicine Advisory Board. Tariq Shah BSc. DipMS is the...
-
Richland, WA, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) announced today that it has been notified by the FDA that RadioGel™ is classified as a device for animal therapy. ...
-
Richland, WA, Jan. 12, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) announced today that it has completed its planned dosing schedule to determine the effectiveness of using the Company’s...